Table 5.
Sensitivity analysis results: canagliflozin 300 mg versus dapagliflozin 10 mg
| Sensitivity analysis | ΔCost ($) | ΔQALY | ICER ($ per QALY gained) |
|---|---|---|---|
| Base case | – 13,991 | 0.08 | Dominating |
| SA1: HbA1c treatment intensification at 7.5% | – 11,706 | 0.07 | Dominating |
| SA2: HbA1c treatment intensification at 8.0% | – 8689 | 0.07 | Dominating |
| SA3: real-world patient characteristics | – 11,786 | 0.07 | Dominating |
| SA4: 20-year time horizon | – 11,646 | 0.07 | Dominating |
| SA5: 10-year time horizon | – 6269 | 0.03 | Dominating |
| SA6: generic price for basal insulin | – 12,974 | 0.08 | Dominating |
AE adverse event, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year